

Application No. 10/815,404  
Amendment dated September 23, 2004  
Preliminary Amendment

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. A pharmaceutical composition comprising an immunogenic A $\beta$  fragment linked to a carrier molecule to form a conjugate, wherein the carrier molecule promotes an immune response comprising antibodies to the A $\beta$  fragment.
2. (Currently Amended) The pharmaceutical composition of claim 1, wherein the A $\beta$  fragment is from the N-terminal half of A $\beta$ .
3. (Currently Amended) The pharmaceutical of claim 2, wherein the A $\beta$  fragment is A $\beta$ 1-5.
4. (Currently Amended) The pharmaceutical of claim 3, wherein A $\beta$ 1-5 consists of the first five N-terminal amino acids of SEQ ID NO:1.
5. (Currently Amended) The pharmaceutical of claim 2, wherein the A $\beta$  fragment is A $\beta$ 1-6.
6. (Currently Amended) The pharmaceutical of claim 5, wherein A $\beta$ 1-6 consists of the first six N-terminal amino acids of SEQ ID NO:1.
7. (Currently Amended) The pharmaceutical of claim 2, wherein the A $\beta$  fragment is A $\beta$ 1-12.
8. (Currently Amended) The pharmaceutical of claim 7, wherein A $\beta$ 1-12 consists of the first 12 N-terminal amino acids of SEQ ID NO:1.
9. (Currently Amended) The pharmaceutical of claim 1, wherein the carrier molecule is a diphtheria toxoid.

Application No. 10/815,404  
Amendment dated September 23, 2004  
Preliminary Amendment

10. (Currently Amended) The pharmaceutical of claim 9, wherein the diphtheria toxoid is CRM 197.
11. (Currently Amended) The pharmaceutical of claim 2, wherein the carrier molecule is a diphtheria toxoid.
12. (Currently Amended) The pharmaceutical of claim 11, wherein the diphtheria toxoid is CRM 197.
13. (Currently Amended) The pharmaceutical of claim 12, wherein the A $\beta$  fragment is A $\beta$ 1-5.
14. (Currently Amended) The pharmaceutical of claim 13, wherein A $\beta$ 1-5 consists of the first five N-terminal amino acids of SEQ ID NO:1.
15. (Currently Amended) The pharmaceutical of claim 12, wherein the A $\beta$  fragment is A $\beta$ 1-6.
16. (Currently Amended) The pharmaceutical of claim 15, wherein A $\beta$ 1-6 consists of the first six N-terminal amino acids of SEQ ID NO:1.
17. (Currently Amended) The pharmaceutical of claim 12, wherein the A $\beta$  fragment is A $\beta$ 1-12.
18. (Currently Amended) The pharmaceutical of claim 17, wherein A $\beta$ 1-12 consists of the first 12 N-terminal amino acids of SEQ ID NO:1.
19. (Currently Amended) The pharmaceutical of claim 1, which comprises greater than 10  $\mu$ g of the A $\beta$  fragment.
20. (Currently Amended) The pharmaceutical of claim 1, which comprises at least 20  $\mu$ g of the A $\beta$  fragment.

Application No. 10/815,404  
Amendment dated September 23, 2004  
Preliminary Amendment

21. (Currently Amended) The pharmaceutical of claim 1, which comprises at least 50 µg of the A $\beta$  fragment.

22. (Currently Amended) The pharmaceutical of claim 1, which comprises at least 100 µg of the A $\beta$  fragment.

23. (Currently Amended) The pharmaceutical of claim 10, which comprises greater than 10 µg of the A $\beta$  fragment.

24. (Currently Amended) The pharmaceutical of claim 10, which comprises at least 20 µg of the A $\beta$  fragment.

25. (Currently Amended) The pharmaceutical of claim 10, which comprises at least 50 µg of the A $\beta$  fragment.

26. (Currently Amended) The pharmaceutical of claim 10, which comprises at least 100 µg of the A $\beta$  fragment.

27. (Currently Amended) The pharmaceutical of any one of claims 2, 3, 5, or 7, which comprises greater than 10 µg of the A $\beta$  fragment.

28. (Currently Amended) The pharmaceutical of any one of claims 2, 3, 5, or 7, which comprises at least 20 µg of the A $\beta$  fragment.

29. (Currently Amended) The pharmaceutical of any one of claims 2, 3, 5, or 7, which comprises at least 50 µg of the A $\beta$  fragment.

30. (Currently Amended) The pharmaceutical of any one of claims 2, 3, 5, or 7, which comprises at least 100 µg of the A $\beta$  fragment.

31. (New) The pharmaceutical composition of claim 1, wherein the conjugate is expressed as a fusion protein.

Application No. 10/815,404  
Amendment dated September 23, 2004  
Preliminary Amendment

32. (New) The pharmaceutical composition of claim 31, wherein the amino terminus of the A $\beta$  fragment is linked to the carrier molecule.

33. (New) The pharmaceutical composition of claim 31, wherein the carboxyl terminus of the A $\beta$  fragment is linked to the carrier molecule.

34. (New) The pharmaceutical composition of claim 1, wherein the A $\beta$  fragment is linked to the carrier molecule by chemical crosslinking.